NYSE:ABBVBiotechs
Did AbbVie’s (ABBV) Q4 Beat and RINVOQ Vitiligo Filings Just Reframe Its Immunology Story?
In early February 2026, AbbVie reported past fourth-quarter 2025 results showing sales rising to US$16,618 million and net income improving to US$1,816 million, alongside full-year sales of US$61.16 billion and essentially flat annual net income versus 2024.
Around the same time, AbbVie also filed for U.S. and European approval of RINVOQ for non-segmental vitiligo, underscoring efforts to expand its immunology franchise into an area with no approved systemic treatments.
Next, we examine how...